Table 3 Secondary outcomes in patients with uncomplicated P. falciparum and P. vivax infections treated with AL or DHA/PPQ for P. falciparum, and CQ or DHA/PPQ for P. vivax, Ethiopia, 2017
| Â | P. falciparum | P. vivax | ||
|---|---|---|---|---|
AL n = 102 | DHA/PPQ n = 74 | CQ n = 137 | DHA/PPQ n = 56 | |
Proportion afebrile, n (%) | ||||
 Day 1 | 74 (73%) | 70 (95%) | 130 (95%) | 53 (95%) |
 Day 2 | 102 (100%) | 74 (100%) | 137 (100%) | 56 (100%) |
 Day 3 | 101 (100%) | 74 (100%) | 137 (100%) | 56(100%) |
Proportion parasite-clear, asexual, n (%) | ||||
 Day 2 | 97 (96%) | 74 (100%) | 137 (100%) | 56 (100%) |
 Day 3 | 100 (99%) | 74 (100%) | 137 (100%) | 56 (100%) |
Gametocyte carriage, n (%) | ||||
 Day 2 | 0 (0%) | 1 (1%) | 3 (2%) | 0 (0%) |
 Day 3 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
 Day 7 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
 Day 14 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
 Day 21 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
 Day 28 | 0 (0%) | 0 (0%) | 2 (2%) | 0 (0%) |
 Day 35 | - | 0 (0%) | – | 0 (0%) |
 Day 42 | - | 0 (0%) | – | 0 (0%) |
Mean Hb concentration, g/dl | ||||
 Day 0 | 14.0 | 13.8 | 12.75 | 14.0 |
 Day 14 | 12.5 | 12.7 | 13.0 | 13.6 |
 Day 28 | 12.7 | 13.2 | 13.2 | 14.4 |
 Day 42 | - | 14.3 | – | 14.5 |